// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Comparison of disease status in uk patients with ra receiving tnfi vs cdmard

J. Addison - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Comparison of elisa and multiplex techniques for quantifying a urine biomarkers panel for lupus nephritis in children

E.M. Smith - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Prostaglandin

Comparison of quantitative mri fat-fraction measurement in sij joint on different scanner platforms

A. Bainbridge - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Comparison of the bioavailability of a single dose of certolizumab pegol injected by pre-filled syringe or by electro-mechanical auto-injection e-device: a phase 1, open-label, randomised, parallel group, single-centre bioequivalence study

R. Oliver - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Certolizumab pegol

Complex immunophenotyping stratifies patients with primary sjÖgren’s syndrome, systemic lupus erythematosus and secondary sjÖgren’s syndrome associated with systemic lupus erythematosus into distinct clinically relevant groups with

N. Thompson - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Consensus definitions for mri lesions in the sacroiliac joints of patients with axial spondyloarthritis: first analysis from the assessments in spondyloarthritis international society (ASAS classification cohort

W.P. Maksymowych - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Construct validation of the italian version of the 5-item compliance questionnaire for rheumatology (I-CQR5

D. Azzolina - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Conventional and biologic disease modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomised controlled trials

M.S.M. Persson - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Correlation between components of the das28 score and health assessment questionnaire in early rheumatoid arthritis

C. Thurston - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

Cross-disease meta-analysis in four systemic autoimmune diseases to identify shared genetic etiologies

M. Acosta-Herrera - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Current impact of ethnicity on renal histology and outcome of lupus nephritis

J. Nossent - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus nephritis

N/A

Cystic fibrosis and inflammatory arthritis requiring immunosuppression: a worrying combination?

M.E.T. Ibrahim - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Damage accrual and mortality rates among different age groups in a cohort of patients with lupus

G.A. Ramirez - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Depression and anxiety in an early rheumatoid arthritis inception cohort. associations with epidemiological, socioeconomic and disease features

G.E. Fragoulis - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Depressive symptoms in patients with rheumatoid arthritis in sarilumab target and mobility trials and impact of treatment

V. Strand - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Depression

Sarilumab

Development and adaptation of rheumabuddy for young people with jia, their families and people with ra residing in the uk

A Gilbert - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Development and preliminary validation of an omeract mri enthesitis scoring system for the ankle in spondyloarthritis

A.J. Mathew - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Spondyloarthritis

N/A

Development and validation of a deep learning algorithm for classifying anti-nuclear antibody patterns in indirect immunofluorescence images

C.-H. Lin - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Development of a national service for biologic drug monitoring

M.E. Perry - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Adalimumab

Development of an online self-management platform for people with rheumatic and musculoskeletal conditions (MSKHUB.COM

Y Prior - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved